Journal: Journal of the Endocrine Society
Article Title: Insulin receptor trafficking and interactions in muscle cells
doi: 10.1210/jendso/bvag020
Figure Lengend Snippet: Analysis of INSR tracks colocalized or not colocalized with CAV1 or CLTC. (A) INSR tracks that colocalized with CAV1 under 0 or 2 nM insulin (referred to as CAV1.Y.0nM or CAV1.Y.2nM below). (B) INSR tracks that colocalized with CLTC under 0 or 2 nM insulin (referred to as CLTC.Y.0nM or CLTC.Y.2nM below). (C) Diffusion coefficient (μm 2 /s) of INSR-B-TagBFP tracks that did not colocalize with CAV1-mRFP tracks under 0 nM insulin (CAV1.N.0nM) or 2 nM insulin (CAV1.N.2nM) or colocalized with CAV1-mRFP tracks under 0 nM insulin (CAV1.Y.0nM) or 2 nM insulin (CAV1.Y.2nM). The cumulative probability shows the distribution of the measurements, with the dots and numbers showing the median values (same for other cumulative probability plots). (D) Diffusion coefficient (μm 2 /s) of INSR-B-TagBFP tracks that did not colocalize with CLTC-mRFP tracks under 0 nM insulin (CLTC.N.0nM) or 2 nM insulin (CLTC.N.2nM) or colocalized with CLTC-mRFP tracks under 0 nM insulin (CLTC.Y.0nM) or 2 nM insulin (CLTC.Y.2nM). (E) Track radius of INSR-B-TagBFP tracks that did not colocalize with CAV1-mRFP tracks under 0 nM insulin (CAV1.N.0nM) or 2 nM insulin (CAV1.N.2nM) or colocalized with CAV1-mRFP tracks under 0 nM insulin (CAV1.Y.0nM) or 2 nM insulin (CAV1.Y.2nM). (F) Track radius of INSR-B-TagBFP tracks that did not colocalize with CLTC-mRFP tracks under 0 nM insulin (CLTC.N.0nM) or 2 nM insulin (CLTC.N.2nM) or colocalized with CLTC-mRFP tracks under 0 nM insulin (CLTC.Y.0nM) or 2 nM insulin (CLTC.Y.2nM). (G) Lifetime of INSR-B-TagBFP tracks that did not colocalize with CAV1-mRFP tracks under 0 nM insulin (CAV1.N.0nM) or 2 nM insulin (CAV1.N.2nM) or colocalized with CAV1-mRFP tracks under 0 nM insulin (CAV1.Y.0nM) or 2 nM insulin (CAV1.Y.2nM). (H) Lifetime of INSR-B-TagBFP tracks that did not colocalize with CLTC-mRFP tracks under 0 nM insulin (CLTC.N.0nM) or 2 nM insulin (CLTC.N.2nM) or colocalized with CLTC-mRFP tracks under 0 nM insulin (CLTC.Y.0nM) or 2 nM insulin (CLTC.Y.2nM). (CAV1.N.0nM, n = 2 cells, 125 tracks; CAV1.N.2 nM, n = 2 cells, 96 tracks; CAV1.Y.0nM, n = 2 cells, 235 tracks; CAV1.Y.2nM, n = 2 cells, 228 tracks; CLTC.N.0nM, n = 4 cells, 597 tracks; CLTC.N.2nM, n = 2 cells, 91 tracks; CLTC.Y.0nM, n = 4 cells, 320 tracks; CLTC.Y.2nM, n = 2 cells, 55 tracks.) (2-ANOVA: # effect of colocalization, $ effect of insulin, % interaction of the 2 variables; Kolmogorov–Smirnov [KS] test: * P < .05, *** P < .0005.) Experiments shown were conducted in Ringer's buffer.
Article Snippet: Proteins were then transferred to polyvinylidene fluoride (PVDF) membranes (Bio-Rad, CA) and probed with antibodies against p-ERK1/2 (Thr202/Tyr204) (1:1000, Cat. #4370, RRID: AB_2315112), ERK1/2 (1:1000, Cat. #4695, RRID: AB_390779), p-AKT (Ser473) (1:1000, Cat. #9271, RRID: AB_329825), p-AKT (Thr308) (1:1000, Cat. #9275, RRID: AB_329828), AKT (1:1000, Cat. #9272, RRID: AB_329827), INSR-β subunit (1:1000, Cat. #3020S, RRID: AB_2249166), p-INSRβ (Tyr1150/1151) (1:1000, Cat. #3024, RRID: AB_331253), FOXO1 (1:1000, Cat. #2880, RRID: AB_2106495), p-FOXO1 (Thr24) (1:1000, Cat. #9464, RRID: AB_329842), all from Cell Signaling (CST), and β-tubulin (1:2000, Cat. #T0198, Sigma, RRID: AB_477556).
Techniques: Diffusion-based Assay